Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced or Metastatic Gastric Cancer
NCT01512745Phase 3Completed
- Sponsor
- Hengrui
- Start
- Jan 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) comparing Apatinib Arm with Placebo Arm (2 arms). Primary endpoints: Progression Free Survival at 30 months and Overall Survival at 30 months. Started Jan 2011; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01512745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01512745.